125 related articles for article (PubMed ID: 24070462)
21. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy.
Wedding U; Ködding D; Pientka L; Steinmetz HT; Schmitz S
Crit Rev Oncol Hematol; 2007 Oct; 64(1):1-9. PubMed ID: 17613243
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
23. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C
Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912
[TBL] [Abstract][Full Text] [Related]
24. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
26. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center.
Karadeniz C; Oguz A; Citak EC; Uluoglu O; Okur V; Demirci S; Okur A; Aksakal N
Pediatr Hematol Oncol; 2007 Sep; 24(6):417-30. PubMed ID: 17710659
[TBL] [Abstract][Full Text] [Related]
28. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
Nabhan C; Smith SM; Helenowski I; Ramsdale E; Parsons B; Karmali R; Feliciano J; Hanson B; Smith S; McKoy J; Larsen A; Hantel A; Gregory S; Evens AM
Br J Haematol; 2012 Jan; 156(2):196-204. PubMed ID: 22084970
[TBL] [Abstract][Full Text] [Related]
29. Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.
Cuttica A; Zallio F; Ladetto M; Di Nicola M; Caracciolo D; Magni M; Marinone C; Dell'Aquila M; Rosace M; Pileri A; Boccadoro M; Gianni AM; Tarella C
Cancer; 2003 Sep; 98(5):983-92. PubMed ID: 12942566
[TBL] [Abstract][Full Text] [Related]
30. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
31. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
Todeschini G; Tecchio C; Pasini F; Benedetti F; Cantini M; Crippa C; Draisci M; Pizzolo G
Cancer; 2005 Aug; 104(3):555-60. PubMed ID: 15959910
[TBL] [Abstract][Full Text] [Related]
32. Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: Major impact of cognition.
Dubruille S; Libert Y; Roos M; Vandenbossche S; Collard A; Meuleman N; Maerevoet M; Etienne AM; Reynaert C; Razavi D; Bron D
J Geriatr Oncol; 2015 Sep; 6(5):362-9. PubMed ID: 26277114
[TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification.
Baars JW; de Jong D; Willemse EM; Gras L; Dalesio O; v Heerde P; Huygens PC; vd Lelie H; Kr vd Borne AE
Br J Cancer; 1999 Apr; 79(11-12):1770-6. PubMed ID: 10206291
[TBL] [Abstract][Full Text] [Related]
34. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
36. Management and Outcomes of Older Patients (Age ≥ 70 Years) with Advanced Soft Tissue Sarcoma and Role of Geriatric Assessment and Oncological Multidimensional Prognostic Index (Onco-MPI) in a Real-World Setting.
Chiusole B; Tortorelli I; Galiano A; Murtas F; Ahcene-Djaballah S; Tierno G; Bergo E; Banzato A; Gatti M; Di Maggio A; Sergi G; Rastrelli M; Sbaraglia M; Zagonel V; Brunello A
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831386
[No Abstract] [Full Text] [Related]
37. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.
Shimada K; Matsue K; Yamamoto K; Murase T; Ichikawa N; Okamoto M; Niitsu N; Kosugi H; Tsukamoto N; Miwa H; Asaoku H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T
J Clin Oncol; 2008 Jul; 26(19):3189-95. PubMed ID: 18506023
[TBL] [Abstract][Full Text] [Related]
39. Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.
Ezzat H; Filipenko D; Vickars L; Galbraith P; Li C; Murphy K; Montaner JS; Harris M; Hogg RS; Vercauteren S; Leger CS; Zypchen L; Leitch HA
HIV Clin Trials; 2007; 8(3):132-44. PubMed ID: 17621460
[TBL] [Abstract][Full Text] [Related]
40. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
